Key Highlights

  • Craneware plc (LSE:CRW) shares rose 2.55% on 5 October 2026 as the healthcare software group continued to recover from its FY26 reset.
  • FY26 Revenue was flat at $206.0 million, while adjusted EBITDA rose 3% to $67.1 million with a 33% margin.
  • Annual Recurring Revenue reached about $185 million, with 100% net revenue retention and customer retention above 90%.
  • Management has rebased FY27 expectations to its recurring revenue level and launched a comprehensive cost review while committing to margins of 30% or more.
  • A Partnership with Microsoft is expected to accelerate AI and sales initiatives, with growth expected to resume in FY28.

Why Craneware Shares Moved Higher on 5 October 2026

Craneware plc (LSE:CRW) gained 2.55% on 5 October 2026, extending a rebound that began after its full-year results on 21 September. The Edinburgh-based company provides financial performance software to US hospitals, and its shares had fallen sharply as 340B drug-pricing headwinds and a cyber incident weighed on sentiment. Investors appear to be refocusing on the resilience of its recurring revenue and cash generation.

FY26 Results: Disappointing but Resilient

Craneware reported FY26 revenue of $206.0 million, flat against $205.7 million. Chief Executive Keith Neilson said the company was deeply disappointed by the results, urging investors not to overlook the strong foundations. Adjusted EBITDA rose 3% to $67.1 million, a 33% margin, and operating cash conversion was 98%. The shares rose 5.6% after the results as the market welcomed clarity.

340B Headwinds and Cyber Incident

Management attributed the late-year slowdown to drug manufacturers restricting Supply at 340B pricing, which reduced transactional revenue from its 340B programme. In July 2026, Craneware identified and responded to a cyber security incident. The company said threat actors were removed within 24 hours and operations continued, although some staff, customer and patient details were among files taken. The full financial impact is still being assessed.

Resetting Expectations and Cutting Costs

Craneware has rebased FY27 revenue expectations to its recurring revenue base of about $185 million, providing greater certainty. A comprehensive cost review aims to align expenses with revised revenue while maintaining EBITDA margins of at least 30%. Growth is expected to resume in FY28 as market uncertainties resolve and product investments pay off.

AI and Microsoft Partnership

Craneware's partnership with Microsoft is expected to accelerate its AI capabilities and sales reach. Its platform helps hospitals manage revenue integrity, pharmacy spend and compliance, areas where AI-driven insights can deliver significant value.

Why Investors Are Watching LSE:CRW

Investors are watching Craneware because its shares have de-rated sharply while the recurring revenue base, retention and margins remain strong. Progress on cost savings, clarity on the cyber incident and any easing of 340B pressures could drive a recovery. The AGM in November 2026 will be the next update point.

Risks to Consider

Regulatory and legal changes around 340B remain uncertain, and the cyber incident could bring additional costs or customer concerns. Growth is not expected until FY28, testing investor patience.

Outlook

The 2.55% gain on 5 October 2026 suggests investors are starting to look past the reset at Craneware plc (LSE:CRW). Execution on the cost review and stabilisation of 340B revenue will be crucial.